Related Experiment Video

Updated: Jul 6, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Target specificity and off-target effects as determinants of cancer drug efficacy

Maria C Shoshan1, Stig Linder

  • 1Cancer Center Karolinska, Department of Oncology-Pathology, Karolinska Institute, S-171 76 Stockholm, Sweden.

Expert Opinion on Drug Metabolism & Toxicology
|March 28, 2008
PubMed

Insights

Targeted cancer therapies, including single-molecule inhibitors and those affecting multiple cellular targets, show promise. Understanding the full spectrum of drug effects is crucial for effective cancer treatment and managing toxicity.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted therapeutics aim for specific cellular targets.
  • Single-molecule inhibitors (e.g., EGFR, IGF-R1) often have limited efficacy in solid tumors.
  • Some targeted agents, like signaling inhibitors for renal carcinoma, demonstrate clinical success.

Purpose of the Study:

  • To explore the efficacy and mechanisms of targeted anticancer agents.
  • To highlight the complexity of drug action beyond single targets.
  • To emphasize the importance of understanding the full spectrum of drug effects.

Main Methods:

  • Review of existing literature on targeted therapeutics.
  • Analysis of clinical activities of various anticancer agents.
  • Comparison of single-target vs. multi-target inhibition strategies.

Main Results:

  • Single-target inhibitors show variable clinical activity.
  • Multi-target inhibitors and those affecting complex cellular pathways (proteasome, HSP90, HDAC) exhibit promising results.
  • Effective targeted agents often resemble conventional chemotherapeutics with multiple targets.

Conclusions:

  • The efficacy of targeted anticancer agents is linked to their spectrum of cellular effects.
  • Understanding comprehensive drug action is fundamental for optimizing cancer therapy and predicting toxicity.
  • Future research should focus on the multifaceted impact of anticancer drugs.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...